Summary A collaborative, hospital-based case-control study was 
The results of studies of oral contraceptives and breast cancer have recently been reviewed and quantitatively summarised (Prentice & Thomas, 1987; Thomas, 1988) . Sixteen case-control and four cohort studies all found no significant increase in risk of breast cancer in women who have ever taken oral contraceptives. Of six case-control studies that assessed risk in users of more than 10 years' duration, four found no increase in risk in such users, and although one found a significantly increased risk, another found a significant reduction in risk. Risk of breast cancer was not found to be altered from 10 to more than 20 years after initial use of oral contraceptives in eight case-control and two cohort studies.
Despite these consistent and reassuring findings, there remain legitimate concerns that oral contraceptives may enhance risk of breast cancer under some circumstances of use. Findings from 14 studies that have assessed risk of breast cancer in women who used oral contraceptives before their first live birth or full-term pregnancy are inconsistent, with eight showing no significant elevation in risk associated with such use Hennekens et al., 1984; Stadel et al., 1985; Lipnick et al., 1986; Meirik et al., 1986; Paul et al., 1986; Miller et al., 1986; Jick et al., 1989) , four finding a significant trend of increasing risk with months of use before the woman's first birth (Paffenbarger et al., 1980; Pike et al., 1981; Harris et al., 1982; McPherson et al., 1987) and two (Miller et al., 1989 ; UK National Case-Control Study Group, 1989) finding an increased risk in young women who used oral contraceptives both before and after their first term pregnancy. Three case-control studies have also found an increase in risk in women who first used oral contraceptives before age 25 (Pike et al., 1983; Olsson et al., 1985; Meirik et al., 1986) , although four others have not (Paul et al., 1986; Cancer and Steroid Hormone Study (CASH), 1986; Miller et al., 1986 Miller et al., , 1989 . Since the reasons for these discrepant findings are unknown, the influence of oral contraceptives when used early in a woman's reproductive life on subsequent risk of breast cancer requires further evaluation.
Another unresolved concern is whether women who are at increased risk of breast cancer should take oral contraceptives. Studies have not shown oral contraceptives to be associated with an increase in risk of breast cancer in women who are nulliparous, had their first child late in reproductive life, or had a family history of breast cancer (Thomas, 1988) . Most studies have also not found an increase in risk in relation to oral contraceptive use in women with a prior history of benign breast disease (Kelsey et al., 1978; Brinton et al., 1982; Vessey et al., 1983; Rosenberg et al., 1984; CASH, 1986) , including the two that specifically assessed risk in women who used oral contraceptives after a benign breast lesion developed (Brinton et al., 1982; CASH, 1986) . Lees et al. (1978) , however, did find an increasing risk with duration of use in women with prior benign lesions and Paffenbarger et al. (1980) reported a similar result, but with a less striking trend, in premenopausal women only ; Miller et al. (1989) also found an increase in risk in users with prior cystic disease. Pike et al. (1981) reported risk in relation to use before a woman's first term pregnancy to be particularly enhanced in women with a history of benign breast disease. These findings require confirmation. Also, the possible influence of oral contraceptives on risk of breast cancer in women with and without other risk factors for breast cancer should be evaluated.
Finally, almost all prior studies of breast cancer have been conducted in economically developed countries with relatively high incidence rates of this disease, and it is not certain that results from such studies are applicable to less developed countries where rates of breast cancer tend to be lower, and where the primary determinants of risk and patterns of use of oral contraceptives may be different from those in more developed countries. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives was conducted, in part, to determine whether findings from studies of oral contraceptives and cancer in developed countries are similar to those from less developed parts of the world. This paper is a report of results from countries with varying levels of economic development that addresses these outstanding issues regarding combined oral contraceptives and breast cancer.
Methods
The methods used in this study have been previously described (WHO Collaborative Study of Neoplasia and Steroid Contraceptives, 1985) . Data were collected in 12 participating centres in Australia, Chile, the People's Republic of China, Colombia, the German Democratic Republic (GDR), Israel, Kenya, Mexico, the Phillippines and Thailand. Data were collected from three separate centres in Thailand (Siriraj and Chulalongkorn in Bangkok, and Chiang Mai). Some centres were individual hospitals; in others, data were collected from more than one hospital. Data (Breslow & Day, 1980, p. 192) Of the 2,116 cases, 579 (27.4%) had ever used combined oral contraceptives, and an additional 141 (6.7%) had used only oral contraceptives of an unknown type. Among the 13,072 controls, 3,671 (28.1%) had ever used combined oral contraceptives, and 756 (5.8%) others had only used unknown types. Of the women who had used combined products, 6.6% of the case users and 3.4% of the control users had also used sequential or continuous preparations; and 5.3% of the case users and 4.7% of the control users had also used oral contraceptives of unknown type. Only 3.3% of the total cases and 1.7% of the total controls had used only sequential products, and just 1.0% of the cases and 0.6% of the controls had used only continous types.
The relative risk of breast cancer in women who ever used combined oral contraceptives was estimated to be 1.15 (1.02, 1.30) after controlling for age and centre. Since most contraceptives of known type were combined preparations, it can safely be assumed that most of the unknown types were actually combined products. Also, the age and centre adjusted relative risk of breast cancer in women who ever used unknown type oral contraceptives was estimated to be 1.12 (0.93, 1.35), which is very similar to the value for combined products. Therefore, use of either combined or unknown types of oral contraceptives was assumed to represent exposure to combined oral contraceptives. Using this definition of exposure, the relative risk was again found to be 1.15, after controlling for age and centre. This definition of exposure to combined oral contraceptives was used in all subsequent analyses presented in this report.
The age adjusted estimates of the relative risks were not found to differ significantly among centres. Data from all centres were therefore combined in analyses to identify and control for confounding variables. When age, centre and the variables age at first live birth and nulliparity (as a single variable), socio-economic index, calendar year of marriage and use of an IUD were added into regression models, each was found to have confounding effects on the relative risk after controlling for the other variables in the model. These effects, however, were not in a uniform direction, and the final estimate of the relative risk based on this model was identical to that obtained when controlling only for age and centre. It is shown at the bottom of Table III. Calendar year of marriage was considered a confounder because availability of oral contraceptives has changed over time, and there have been temporal changes in incidence rates of breast cancer in some countries. Use of an IUD was not suspected a priori to be a confounding variable, and controlling for all of the variables in the final model except use of an IUD resulted in an estimate of the relative risk of 1.12 (1.00, 1.26). Unless otherwise stated, the results presented subsequently are based on analyses in which use of an IUD was included as a confounding variable, but in all instances, results were similar to those obtained when estimates of relative risks were not controlled for IUD use.
A large number of other variables related to menstruation, child bearing, socio-economic status, access to medical ser- Table VII , the estimated relative risk of breast cancer in women under age 35 who ever used oral contraceptives is 1.26. The estimated relative risk for older women, using the original model to analyse data separately from such women, was 1.12. These two values do not differ significantly (P value of X2 test for heterogeneity = 0.38). The mean of these two estimates weighted by the inverse of their variance provides an overall estimate of 1.14 (1.02, 1.27). Because this estimate is similar to the overall estimated relative risk of 1.15, the original model was used in analyses that included women of all ages. Analyses of data on women under age 35 were based on the model developed for that age group.
A relative risk of greater than I in women under age 35 was observed in seven of the 10 centres from which sufficient data were available to provide an estimate of the relative risk in such women, and a X2 test for heterogeneity showed the variation in the estimates for the various centres to be explainable on the basis of chance (P = 0.36). The relative risks in relation to years of use, time since first use and time since last use were not consistently greater in women less than 35 than in older women, and the trend of increasing risk with duration of use shown in Table IV for women of all ages was no stronger in the younger than older groups of women.
As shown in Table VII , no statistically significant interactions were observed between use of oral contraceptives and age at first live birth and nulliparity, outcome of first pregnancy, socio-economic index or family history of breast cancer.
The effect on risk of breast cancer of use of oral contraceptives before and after a biopsy for a benign breast lesion was assessed from data on the 174 cases and 406 controls who gave a history of such a lesion. Use before their benign lesion was reported by 31 cases and 77 controls; and use afterwards was reported by 26 cases and 68 controls. The relative risk of breast cancer was not significantly enhanced either in women who used oral contraceptives before their prior breast biopsy (RR = 1.30; 95% CI = 0.75, 2.27) or after (RR = 0.97; 95% CI = 0.54, 1.72). These estimates were calculated controlling for the same variables as in Table III . (Muir et al., 1987) . The seven other countries are either known to have lower incidence rates of breast cancer, or can reasonably be assumed to have low rates because of their adjacency and economic similarity to known low incidence nations (Waterhouse et al., 1982; Muir et al., 1987) .
As shown in Table VIII (Skegg, 1988) Among all cases in this study, 43.3% of those who had ever used oral contraceptives presented with small tumours (<3 cm), compared to 38.3% of non-users. However, after adjusting for confounding variables considered in previous analyses, relative risks were not found to be enhanced predominantly for smaller tumours in all women who ever used oral contraceptives, in users under age 35, or in users in developing countries. Risk in users was also not preferentially enhanced for tumours confined to the breast compared to tumours with local spread or distant metastasis. Also, the increases in risk in relation to long-term, current and recent use of oral contraceptives were observed for tumours of all sizes. It is therefore unlikely that selective detection of cases in women who used oral contraceptives can explain the observed overall increase in risk, or the possible increases in young women, in developing countries, or in long-term, recent and current users.
Tumours in women who used oral contraceptives for more than 36 months before they were 25 years old tended to be small (73.9% of 23 of known size were less than 3 cm in diameter), although tumours in users of 25-36 months' duration, who had an equally high relative risk, did not (37.5% of 24 tumours were less than 3 cm). Thus, preferential screening in young women who have been long-term users of oral contraceptives may partly account for the findings in the upper part of Table IX, but it is probably not the total explanation. On the other hand, women with a prior nonviable pregnancy before their first live birth, who used oral contraceptives before their first live birth, more frequently had small tumours (less than 3 cm in diameter) than similar women who had not used oral contraceptives before their first live birth (59.2% of 13 tumours of known size vs 33% of 15 tumours). Also, in users before their first live birth with a prior non-viable pregnancy, age and centre adjusted relative risks were 4.44 (1.35, 14.6), 1.33 (0.26, 6 .95) and 0.74 (0.08, 7.05) for tumours that were <3, 3-4 and >4 cm in diameter, based respectively on nine, three and one exposed cases, and 47 exposed controls. The small increase in risk in relation to use before a first live birth (Table IX) may therefore be due to selective early diagnosis of breast cancer in women with such use, if they had had a prior non-viable pregnancy.
Composition of oral contraceptives Details of results in relation to oral contraceptives of varying compositions will be the subject of a separate report, and only observations of value in interpreting the findings presented in this paper are summarised here. Relative risks of breast cancer in relation to 22 different combined oral contraceptives were estimated from data on non-users and women who had used a single (known) combined product. Relative risks in women who ever used these products were less than 1 for nine formulations, and greater than 1 for 13. The relative risks ranged from 0.74 to 1.43 among 21 pill types, and a relative risk of 8.19 (1.94, 34.6), based on four exposed cases and five exposed controls, was observed for one product (1 mg lynestrenol plus 0.1 mg mestranol). The products associated with the higher relative risks tended to be those used more frequently both in women under age 35 and in developing countries. However, the products associated with high relative risks did not differ consistently from those associated with lower relative risks by type of oestrogen or progestagen, or by the dosages of either of these constituents. Also, it was possible to estimate relative risks in relation to three specific formulations both for women under age 35 and for older women; and the relative risks in users of all three products were higher in the younger than in the older age group. Similarly, the relative risks were higher in developing than developed countries for both of the formulations for which it was possible to make individual estimates of the relative risk in each of the two groups of countries. It is therefore unlikely that any differences in relative risks associated with oral contraceptives in developed and developing risk countries and in younger and older women are due to use of different oral contraceptives with different degrees of carcinogenicity for the breast.
There were too few data for analysis to determine whether the enhanced risks shown in Table IX are specific for particular types of oral contraceptives.
Discussion
Estimates of the relative risk of breast cancer in women who ever used oral contraceptives were recently estimated to be 1.0 (0.9, 1.1) and 1.0 (0.8, 1.1) based on combined data from 16 previous case-control and four cohort studies, respectively (Thomas, 1988) . Nearly all of these prior studies were conducted in developed countries with relatively high rates of breast cancer. Although the relative risk of 1.15 (1.02, 1.29) estimated in this study is not incompatible with these summary estimates, it is higher than that found in most prior investigations. The estimates for women in developed and developing countries in this study did not differ significantly, but the value for developing countries was the higher of the two, and contributed to most of the possible small overall elevation in risk that was observed. The estimated relative risk of 1.07 (0.81, 1.26) in women in the three developed countries who ever used oral contraceptives is close to the summary estimates of Thomas (1988) . Also, the relative risk of 0.9 in women in these three countries who were initially exposed over 15 years previously is identical to the value estimated from the eight prior case-control studies that provided relative risks for women initially exposed from over 10 to over 20 years in the past (Thomas, 1988) . In contrast, the point estimate of the relative risk for women in the developing countries was 1.24 (1.05, 1.47) in women who ever used oral contraceptives and this is greater than values obtained from all but four (Kelsey et al., 1978; Pike et al., 1981; Miller et al., 1989; UK National Case-Control Study Group, 1989) of 19 previous case-control studies, and from all but one (Kay & Hannaford, 1988) of four previous cohort studies (Thomas, 1988; Kay & Hannaford, 1988; Vessey et al., 1989) conducted in developed countries. Results from the few studies of oral contraceptives and breast cancer in developing countries (Lee et al., 1987; Yuan et al., 1988) have yielded inconsistent results. Since the results from this study, particularly those from developing countries, may be at variance with results from most prior investigations, possible reasons for a spurious increase in risk must be considered.
Because this study was conducted in part in countries with limited medical care facilities, some cases may not come to medical attention. If such cases were also those less likely to have received other medical services, including family planning services, then the (hospitalised) cases included in this study would be more likely to have used oral contraceptives than the hypothesised missed cases, and this could result in a spurious increase in relative risk in relation to oral contraceptive use. This possible source of bias was anticipated when the study was planned, and resulted in the decision to select hospital controls, rather than controls from the same village or neighbourhood as the cases. This as least partly controlled for (unknown) factors that determine entry into the medical care system and admission to the hospitals in which the study was conducted. Information was also obtained on various indices of medical care utilisation, such as prior pap smears and chest X-rays, and control for these factors did not alter the estimated values of the relative risks in oral contraceptive users.
Conversely, a bias in the opposite direction could have resulted because some hospitals served both as referral centres for such serious and relatively unusual conditions as breast cancer, and also as local, general hospitals; and if access to contraceptive services is better in areas in proximity to the hospital than in more distant regions, and if cases came from a wider catchment area than the controls, then this would lead to a spuriously low relative risk. To reduce the possibility of this source of bias, cases and controls were restricted to defined geographical areas served by the hospitals. These areas were often quite large, however. To reduce further the possibility of this source of bias, a detailed residential history was ascertained for all study subjects, so that estimates of relative risks could be controlled for place of residence (urban centre, town, rural village) and mobility. Controlling for such variables did not alter the results of this study.
Another possible explanation for a spurious increase in relative risk is that the hospital controls had diseases that were associated with under-use of oral contraceptives. To reduce this source of bias, individuals who were hospitalised for conditions known or perceived to be related to use of oral contraceptives, or contra-indications to their use, were not eligible for selection as controls. Furthermore, the controls consisted of women with a large variety of medical conditions, and use of oral contraceptives did not vary greatly among women in the various diagnostic categories. Under-utilisation of oral contraceptives in some diagnostic groups of controls therefore cannot explain the observed increase in relative risk.
Bias due to more intensive screening for breast cancer in oral contraceptive users than in non-users also cannot explain the overall increase in relative risk observed, or the increase in long-term users, or in recent and current users. The relative risks in relation to these features of use did not vary appreciably by tumour size or stage of disease at diagnosis. Also, non-invasive carcinomas were not considered in this report, in part because they would be the most likely malignancies to be detected by screening.
Another possible reason for a spuriously enhanced relative risk is more complete recall of prior use of oral contraceptives by cases than controls. Utilisation of hospitalised women as controls reduced the possibility of this occurring. Furthermore, if this had occurred, one would also expect to observe an enhanced relative risk of other cancers in relation to oral contraceptives. On the contrary, use of oral contraceptives has been found in this study to be associated with a reduced risk of cancer of the endometrium (WHO Collaborative Study of Neoplasia and Steroid Contraceptives, 1988) and ovary (WHO Collaborative Study of Neoplasia and Steroid Contraceptives, 1989) and the estimates of the relative risks of these neoplasms in users of oral contraceptives are similar in magnitude to those from prior studies (Prentice & Thomas, 1987 Spurious results could also have resulted from confounding by risk factors for breast cancer that are also related to use of oral contraceptives. This is unlikely because most of the known risk factors for breast cancer were considered, and information on them was most probably correctly ascertained, because these factors were found to be related to breast cancer in this study (Table II) . Possible risk factors that were not considered are obesity and high fat diet. Obesity is an unlikely confounder in this study because most women were relatively young, and obesity has been most strongly and consistently related to breast cancer in postmenopausal women. Although national rates of breast cancer have been correlated with consumption of animal fats and other meat products, a high fat diet has been only weakly and inconsistently related to breast cancer in case-control studies, perhaps because the variation in fat intake within countries is relatively small in comparison with international variations in fat consumption (Prentice et al., 1990) . Controlling for centre in this study effectively controlled for differences in fat intake among centres. Control for various indices of socio-economic status would have partly controlled for differences in fat intake between cases and controls within centres. It is thus unlikely that the variation in fat intake among individuals within centres, and the strength of the association between fat intake and breast cancer, would be of sufficient magnitude that residual confounding by fat intake could explain the increased relative risk in users of oral contraceptives.
Chance variation is also unlikely to be the sole explanation for our findings. The 95% confidence intervals of the relative risks in women who ever used oral contraceptives do not include unity, when based either on data from all subjects in the study, or on data from residents of the developing countries; the relative risks were greater than 1 in 10 of the 12 centres, including eight of the nine in developing populations.
Although a combination of chance, and minor sources of bias and confounding, could account for our results, a causal interpretation must also be considered. Although risk was observed to be highest in the longest use category (Table IV) , an increase with duration of exposure was not observed after stratifying on months since most recent exposure (Table VI) . This absence of a trend of increasing risk with duration of use, and lack of an increase in risk with time since first use, are not observations that one would expect if oral contraceptives were involved in initiating a carcinogenic process. In this study, an enhanced risk was observed in current and recent users, and there was a decline in risk with time since last use. Similar observations have been reported at least to some extent from four previous investigations (Fasel et al., 1975; Brinton et al., 1982; Harris et al., 1982; Meirik et al., 1986) , but not from two others (Vessey et al., 1983; Cancer and Steroid Hormone Study, 1986 (Thomas, 1988) . There is thus little or no reason to advise women to avoid using oral contraceptives if they have one or more of these features that are associated with an increased risk.
The difference in the relative risks of 1.07 and 1.24 observed in developed and developing countries, respectively, could be due to chance or to unrecognised sources of bias or confounding that were operative primarily in the less developed countries in which this study was conducted. Alternatively, these findings are compatible with oral contraceptives exerting a small additive effect on risk of equal magnitude in countries with varying underlying rates of breast cancer.
Thus, even if the relative risks are truly higher in the developing countries, the numbers of cases per 100,000 women years of exposure attributable to use of oral contraceptives would not be greater than in the developed countries because of their lower underlying incidence rates.
If oral contraceptives were to enhance risk of breast cancer by only a small absolute number of additional cases per 100,000 women years of use, then it is not surprising that prior studies conducted largely in high rate countries have failed to detect such small increases in risk. Epidemiological methods currently available may not be sufficiently sensitive to do so. Conducting studies in low risk populations is one way to enhance the likelihood of detecting a true, but small, absolute increase in risk, because the relative risk in such populations would be larger than in higher risk populations. The results of this study serve to demonstrate the utility of this approach. They also indicate that further studies of breast cancer and oral contraceptives in low risk populations are warranted to determine whether the findings presented in this report can be replicated.
The possibility that use of oral contraceptives at an early age, or before the birth of a woman's first child, enchances risk of breast cancer has been the subject of considerable study and debate in recent years. Prior investigations have yielded inconsistent results. An increased risk in women who used oral contraceptives before age 25 was found in three studies (Pike et al., 1983; Olsson et al., 1985; Meirik et al., 1986) , but not in four others (Paul et al., 1986; Cancer and Steroid Hormone Study, 1986; Miller et al., 1986 Miller et al., , 1989 . The observed increase in risk in this study, of borderline statistical significance, in women who had used oral contraceptives before age 25 for over 2 years is somewhat supportive of the notion that such use can enhance the development of breast cancer; but the absence of a significant trend of increasing risk with duration of use is not. By considering the size of the tumours of diagnosis, evidence was provided that the observed enhanced risk in long-term users before age 25 is probably not due solely to preferential screening for breast cancer in such women.
Significantly elevated relative risks in women who used oral contraceptives before the birth of their first child have been reported from four independent investigations (Paffenbarger et al., 1980; Pike et al., 1981; Harris et al., 1982; McPherson et al., 1987) , but not from eight others Hennekens et al., 1984; Stadel et al., 1985; Lipnick et al., 1986; Meirik et al., 1986; Paul et al., 1986; Miller et al., 1986; Jick et al., 1989) . A small increase in risk in women who used oral contraceptives for more than 2 years before their first live birth was observed in this study, but this increase was found only in women whose live birth was preceded by a pregnancy with a non-viable outcome, and evidence has been presented that suggests that this observation may be due to preferential screening of such users for breast cancer. No satisfactory explanation has yet been found for the inconsistent results among previous studies regarding use before a woman's first birth. The findings from this study offer a possible explanation, and it would be useful if others would attempt to replicate them. Results from two recent case-control studies (Miller et al., 1989 ; UK National Case-Control Study Group, 1989) showed increased relative risks of breast cancer in young women in relation to use of oral contraceptives, irrespective of whether the use was before or after the birth of the woman's first child. The findings from this study are broadly consistent with these results.
